Recent articles
Curaleaf's Q1 Results: Is the CEO Shift a Reason to Buy the Stock?
The newly named CEO displaces a man who will be heading up an intriguing new business unit at the pot company.
Why Appian Shares Got Slammed On Monday
Although first-quarter results were promising, one researcher has shaved its price target on the company's stock.
Why Axsome Therapeutics Stock Got Mashed on Monday
Investors were hardly impressed with the closing of a rights deal.
Why DocuSign Stock Got Pummeled Today
An executive resignation spooks nervous investors.
Why Tonix Pharmaceuticals Got Crushed Today
Now is not a great time for pre-revenue biotechs to be reporting earnings.
Why Intercontinental Exchange Took a Big Hit After Q1 Results
The New York Stock Exchange's owner is opening its wallet for a new acquisition.
Why Hexo Stock Wilted So Badly This Week
A dilutive new share issue and negative sentiment about pot stocks generally combine for a double-digit share price dip.
Why Blue Apron Was a Tasty Stock This Week
The meal kit specialist delivered a box of good news about its finances.
Why Appian Stock Topped the Market Today
There's nothing like a pair of quarterly beats to make shareholders happy.
Why DoorDash Stock Flopped on Friday
The company beat expectations on first-quarter revenue, but whiffed on the bottom line.
Why Tesla Stock Was Slumping on Friday
The electric vehicle powerhouse might, or might not, be cranking up production at its Shanghai gigafactory.
Why Revolve Group Stock Was Down by Over 20% This Week
Counterintuitively, the shares suffered a big drop after the retailer delivered a better-than-expected first quarter.
Why DraftKings Stock Was a Good Bet This Week
The company is the proud new owner of a complementary online gambling business.
Why Clovis Oncology Stock Was Plummeting This Week
Investors bailed from the company after a quarterly results and operational update.
Why TripAdvisor Soared High Above the Market Today
The company more than doubled its revenue in the inaugural quarter of 2022.
Why Global Blood Therapeutics Stock Was Sickly Today
The bears pounced on the company despite a first-quarter bottom-line beat.
Why BioCryst Stock Lost Nearly 4% of Its Value Today
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
Why Royal Caribbean Got Thrashed on Thursday
The company is indisputably in recovery mode, but it whiffed on first-quarter estimates.
Why eBay Stock Tanked Today
Investors weren't pleased with the company's first-quarter results, to put it mildly.
Teva's Q1 Results: Is the Stock About to Crash?
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.